Tarsus Pharmaceuticals (TARS) Common Equity (2019 - 2026)

Tarsus Pharmaceuticals' Common Equity history runs 8 years deep, the most recent figure standing at $349.0 million for Q1 2026.

• In Q1 2026, Common Equity rose 1.9% year-over-year to $349.0 million; the TTM figure through Mar 2026 stood at $349.0 million (up 1.9% YoY), while the FY2025 annual figure was $343.4 million, up 52.95% from the prior year.
• Common Equity was $349.0 million for Q1 2026 at Tarsus Pharmaceuticals, up from $343.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $349.0 million in Q1 2026 to a low of $147.7 million in Q2 2023.
• Historically, Common Equity has averaged $246.5 million across 5 years, with a median of $224.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Common Equity sank 33.31% in 2023, then soared 70.75% in 2024.
• A 5-year view of Common Equity shows it stood at $192.9 million in 2022, then advanced by 2.12% to $197.0 million in 2023, then advanced by 13.98% to $224.5 million in 2024, then surged by 52.95% to $343.4 million in 2025, then climbed by 1.61% to $349.0 million in 2026.
• The last three Common Equity figures came in at $349.0 million (Q1 2026), $343.4 million (Q4 2025), and $335.1 million (Q3 2025), per Business Quant data.